Dyne Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 44.19 million compared to USD 35.58 million a year ago. Basic loss per share from continuing operations was USD 0.78 compared to USD 0.69 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.6 USD | +0.22% | +9.81% | +137.37% |
09:26am | Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing | MT |
May. 22 | Dyne Therapeutics Prices $325.5 Million Common Stock Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+137.37% | 3.09B | |
+64.21% | 62.59B | |
-1.26% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+13.00% | 26.21B | |
-21.52% | 19.09B | |
+5.51% | 13.08B | |
+25.32% | 12.26B | |
+28.40% | 12.05B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023